What does lenvatinib mainly treat and how is it used?

Lenvatinib, as a multi-target receptor tyrosine kinase (RTK) inhibitor, plays an important role in cancer treatment. It mainly targets malignant tumors that need to inhibit tumor cell angiogenesis and proliferation. Clinically, the drug has been proven to have significant efficacy and good safety. This article will introduce in detail the indications and usage of lenvatinib.

The main treatment areas of lenvatinib include: locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. For these patients, lenvatinib can provide an effective treatment option to help control disease progression.

In the field of hepatocellular carcinoma, lenvatinib is also widely used in the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Its emergence provides these patients with new treatment options that help prolong survival and improve quality of life.

In addition to being used alone, lenvatinib is often used in combination with other drugs to enhance the therapeutic effect. For example, in combination with pembrolizumab, lenvatinib is indicated for the treatment of patients with non-microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer who have progressed after prior systemic therapy and are not candidates for curative surgery or radiation therapy. In addition, the combination regimen plus pembrolizumab is also used in the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), providing patients with more treatment options and better treatment effects. In addition, lenvatinib is also used in combination with everolimus to provide new treatment hope for patients with advanced renal cell carcinoma (RCC) after a prior anti-angiogenic therapy.

When using lenvatinib, you need to strictly follow your doctor's instructions and recommended dosage. Typically, the dose of lenvatinib is adjusted based on the patient's weight and condition. Patients should swallow the medication whole and avoid opening or crushing the capsules. If you have difficulty swallowing, mix the capsules with water or apple juice to form a suspension. At the same time, patients need to pay close attention to their own adverse reactions and communicate with their doctors in a timely manner.

In summary, lenvatinib, as an important anti-tumor drug, has demonstrated significant therapeutic effects in multiple cancer fields. Patients should follow their doctor's instructions when using it to ensure safe and effective treatment. There are many versions of this drug currently available, please choose yourself.